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Abstract: Patients with Marfan syndrome (MFS), a connective tissue disorder caused by pathogenic
variants in the gene encoding the extracellular matrix protein fibrillin-1, have an increased prevalence
of primary cardiomyopathy, arrhythmias, and sudden cardiac death. We have performed an in-depth
in vivo and ex vivo study of the cardiac phenotype of Fbn1mgR/mgR mice, an established mouse
model of MFS with a severely reduced expression of fibrillin-1. Using ultrasound measurements,
we confirmed the presence of aortic dilatation and observed cardiac diastolic dysfunction in male
Fbn1mgR/mgR mice. Upon post-mortem examination, we discovered that the mutant mice consistently
presented myocardial lesions at the level of the right ventricular free wall, which we characterized as
spontaneous pseudoaneurysms. Histological investigation demonstrated a decrease in myocardial
compaction in the MFS mouse model. Furthermore, continuous 24 h electrocardiographic analysis
showed a decreased heart rate variability and an increased prevalence of extrasystolic arrhythmic
events in Fbn1mgR/mgR mice compared to wild-type littermates. Taken together, in this paper we
document a previously unreported cardiac phenotype in the Fbn1mgR/mgR MFS mouse model and
provide a detailed characterization of the cardiac dysfunction and rhythm disorders which are caused
by fibrillin-1 deficiency. These findings highlight the wide spectrum of cardiac manifestations of MFS,
which might have implications for patient care.
Keywords: marfan syndrome; fibrillin-1; cardiac function; myocardial compaction; ventricular
pseudoaneurysm; electrocardiogram; arrhythmia
1. Introduction
The myocardial extracellular matrix (ECM) is a complex fibrous meshwork in close contact with cardiac
myocytes, fibroblasts, leukocytes, and endothelial cells [1], which plays an important role in myocardial
structure and function, thereby continuously adapting to local cell signaling. Together with the fibrillar
proteins collagen, elastin, and fibronectin, fibrillin-1 is an important component of the myocardial ECM
and is believed to be involved in the transmission of forces from the myocardial ECM to the cardiac
myocytes, based on its specific spatial arrangement in the myocardial tissue [2–4]. Pathogenic FBN1 variants
Int. J. Mol. Sci. 2020, 21, 7024; doi:10.3390/ijms21197024 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 7024 2 of 19
resulting in defective fibrillin-1 cause Marfan syndrome (MFS). MFS is an autosomal dominantly inherited
connective tissue disorder associated with life threatening cardiovascular manifestations, of which aortic
dilatation/dissection and mitral valve prolapse are major causes of morbidity and mortality [5–7].
Better clinical management has led to an increased life expectancy for patients with MFS in recent
decades. Nevertheless, combined with improved cardiovascular surveillance, this has revealed additional
MFS-related cardiovascular problems, such as intrinsic myocardial dysfunction and arrhythmia [8–16].
In order to explore these MFS-related cardiac manifestations, several studies have already been performed
in Fbn1C1039G/+ and Fbn1mgR/mgR MFS mouse models [17]. The Fbn1C1039G/+ mouse model is an antimorphic
model resulting from the substitution of a conserved cysteine to a glycine in a calcium-binding EGF-like
domain of Fbn1. Heterozygous Fbn1C1039G/+ mice show a mild, classic MFS phenotype. The Fbn1mgR/mgR
mouse model, on the other hand, is a hypomorphic model. Due to the insertion of a neomycine cassette
between introns 18 and 19 of Fbn1, fibrillin-1 expression is reduced approximately five-fold. Homozygous
Fbn1mgR/mgR mice show an early-onset, severe MFS phenotype.
Cua et al. [18] and Lee et al. [19] demonstrated a significant dilatation of the left ventricle (LV) in the
Fbn1C1039G/+ mouse model by means of optical coherence tomography. Mild LV dilatation, independent of
valvular dysfunction, was also observed by Campens et al. [11] in the same mouse model using ultrasound
analysis. In other studies by Cavanaugh et al. [20] and Rouf et al. [21], a significant increase in the LV
diameter of Fbn1C1039G/+ mice was only observed after a two-week angiotensin II treatment, or after surgical
constriction of the thoracic aorta, respectively. Cook et al. [22], on the other hand, identified a severe primary
dilated cardiomyopathy with significant systolic dysfunction in the Fbn1mgR/mgR mouse model. They also
found a significant broadening of the QRS complex on the electrocardiogram (ECG) of Fbn1mgR/mgR mice in
comparison to their wild-type littermates, suggestive of ventricular conduction delay.
Currently, the number of mouse studies regarding MFS-related myocardial dysfunction and
arrhythmia is limited. Additional research on the cardiac phenotype of MFS mouse models is warranted
as this might lead to novel insights in the underlying pathophysiological processes, which might have
implications for the management of cardiac manifestation of MFS in patients. In this study, we therefore
performed in-depth cardiac phenotyping analyses of the Fbn1mgR/mgR mouse model, which included a
detailed in vivo and ex vivo evaluation of cardiac structure and function.
2. Results
2.1. Ultrasound Analysis of Thoracic Aorta Diameter and Cardiac Function
A marked dilatation was observed at all levels of the thoracic aorta in the Fbn1mgR/mgR (MFS) mice
compared to wild-type (WT) mice, as a hallmark of the MFS phenotype (Table 1). To investigate cardiac
valve function, ultrasound analysis of intracardiac flow patterns was performed. Aortic- and/or mitral
valve regurgitation (presenting as holodiastolic flow reversal at the level of the aortic valve and the
mitral valve, respectively) was observed in 73% of the MFS mice. None of the WT mice presented
significant valve regurgitation.
Cardiac function was also calculated from ultrasound recordings. No significant difference was
found for the LV end-diastolic and end-systolic diameter (LVEDD and LVESD, respectively) between the
WT and MFS mice. In addition, the right ventricular end-diastolic diameter (RVEDD) and LV fractional
shortening (FS) revealed no significant difference between the MFS mice and their WT littermates. However,
a significant decrease of E wave velocity (early filling of the left ventricle) could be observed in the MFS
mice compared to their WT littermates (independent samples test; p = 0.002). As no difference could be
observed in the values of the A wave velocity (late filling of the left ventricle) between the MFS and WT
mice, this decrease in E wave peak amplitude resulted in a decreased E/A ratio in the MFS mice (Table 1).
2.2. Macroscopic Analysis of Cardiac Morphology
Heart weights, normalized to tibia length, showed no significant difference between MFS mice
and their WT littermates at the different ages studied (Figure 1). In addition, macroscopic analysis of
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the dissected hearts revealed no difference in cardiac dimensions (length and width) between the MFS
and WT mice in any of the age groups (Appendix A Figure A1).
Table 1. Physiological parameters of the aorta and cardiac ventricles of wild-type (WT) and Marfan
syndrome (MFS) mice obtained by ultrasound measurements at 3 months of age. Measurements of the
aorta include 12 WT and 12 MFS mice. Measurements of the cardiac ventricles include 5 WT and 6 MFS
mice. p-values were calculated using an independent samples test.
WT MFS p-Value
Ao Diameters
Ao Sinus (mm) 1.61 ± 0.10 2.15 ± 0.09 0.001
Ao Asc (mm) 1.55 ± 0.10 2.89 ± 0.10 <0.001
Arch (mm) 1.43 ± 0.06 2.01 ± 0.06 <0.001
Ao Desc (mm) 1.15 ± 0.07 1.37 ± 0.06 0.038
LVESD (mm) 3.27 ± 0.08 3.24 ± 0.16 ns
LVEDD (mm) 4.20 ± 0.11 4.49 ± 0.17 ns
RVEDD (mm) 1.92 ± 0.10 2.11 ± 0.09 ns
LV FS (%) 22.14 ± 1.30 27.71 ± 2.88 ns
E (mm/s) 625.3 ± 54.2 310.5 ± 56.8 0.002
A (mm/s) 386.3 ± 36.5 382.0 ± 35.3 ns
E/A 1.67 ± 0.14 0.84 ± 0.14 0.002
WT, wild-type; MFS, Marfan syndrome; Ao, aorta; Ao Asc, ascending aorta; Ao Desc, descending aorta; LVESD, left
ventricular end systolic diameter; LVEDD, left ventricular end diastolic diameter; RVEDD, right ventricular end
diastolic diameter; LV FS, left ventricular fractional shortening; E, early left ventricular filling velocity; A, late left
ventricular filling velocity; ns, not significant. Values are mean ± SE.
2.3. Myocardial Structure
2.3.1. Macroscopic Analysis of Ventricular Wall Morphology
Further macroscopic analysis of the hearts revealed the presence of myocardial tears (elongated dark
red lines) and vesicles (dark red vesicular bulging lesion) at the level of the right ventricular (RV) surface
of the MFS mice (Figure 2a–d). Both the tears and the vesicles had a dark red appearance, and the vesicles
expanded slightly during post-mortem reflex contractions of the heart, suggesting a direct connection to
the RV cavity. Interestingly, these lesions were not present in any of the WT mice, whereas the majority of
the hearts of the MFS mice presented these lesions at each age group studied (Figure 2e).
2.3.2. Histological Analysis of Ventricular Wall Lesions
In order to identify the nature of the lesions in the RV free wall, histological staining was performed
on consecutive myocardial tissue sections in which a tear or vesicle was present (Figure 3). Standard HE
staining revealed that both the tear as well as the outer wall of the vesicle (Figure 3a–d) are composed of
a relatively thin layer of epicardial cells embedded in ECM components. The tear consists of a thinned
region in the RV wall lacking cardiac muscle tissue adjacent to the epicardial layer. The vesicle-like
lesions are connected with the lumen of the RV through a small duct between cardiac muscle lamellae
(Figure 3c). Furthermore, in-depth cellular morphology analysis of the HE-stained tissue sections did
not show any evidence of inflammatory cell infiltration at the site of or near the myocardial wall lesions
(Figure 3b,d,e,g). Picrosirius red (PSR) staining (Figure 3f,h), as well as a fluorescent dye (Figure 3i–p),
showed that both the tear and the vesicle wall contain abundant levels of collagen. The cellular border
of these cardiac lesions consists mainly of fibroblasts, as indicated by a positive vimentin staining
(Figure 3i–l), with an inner lining consisting of CD31-positive endothelial cells (Figure 3q,s). Adjacent to
the myocardial tear, a discrete number of cells stained positive for the myofibroblast marker α-smooth
muscle actin (α-SMA, ACTA2) (Figure 3n). Relative to the tear, the number of myofibroblasts is higher
in the wall of the vesicle (Figure 3o,p), where a layer of subendothelial cells was shown to express
α-SMA. No cardiac myocytes were located in the tear nor the vesicle wall, as evidenced by the absence
of α-actinin-2 (ACTN-2) staining (Figure 3r,t, respectively).
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Figure 1. Macroscopic characterization of the heart of WT and MFS mice at 1, 2, and 3 months of age. 
Dot plot visualizes individual heart weight/tibia length ratios and mean value per age and genotype 
(n = 12 per age and genotype). WT and MFS measurements are indicated in grey and black, 
respectively. Error bars represent standard error. Associated p-values are annotated at the top of the 
graph (independent samples test on the mean values of the HW/TL). At the bottom of the figure, 
representative macroscopic pictures of WT and MFS mice hearts collected at 1, 2, and 3 months of age 
are depicted. Scale bar: 2 mm. HW/TL, heart weight to tibia length ratio (g/mm); WT, wild-type; MFS, 
Marfan syndrome. 
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Figure 1. Macroscopic characterization of the heart of WT and MFS mice at 1, 2, and 3 months of age. Dot
plot visualizes individual heart weight/tibia length ratios and mean value per age and genotype (n = 12
per age and genotype). WT and MFS measurements are indicated in grey and black, respectively. Error
bars represent standard error. Associated p-values are annotated at the top of the graph (independent
samples test on the mea values of the HW/TL). At the bott m of the figure, representative macroscopic
pictures of WT and MFS ice hearts collected at 1, 2, and 3 month of ag are depicted. Scale bar: 2 mm.
HW/TL, heart weight to tibia length ratio (g/mm); WT, wild-type; MFS, Marfan syndrome.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 21 
 
 
Figure 2. Macroscopic analysis of the heart of MFS mice. (a,b): macroscopic view of the heart of a MFS 
mouse presenting a tear at the level of the right ventricular wall. The tear is indicated with a white 
arrow in panel (b). (c,d): macroscopic view of the heart of a MFS mouse presenting vesicles at the 
level of the right ventricular wall. Vesicles are indicated with a white arrowhead in panel (d). (e): 
number of WT and MFS mice presenting cardiac lesions per age group. Scale bar of panels (a,c) = 1 
mm, scale bar of panels (b,d) = 250 µm. 
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Figure 2. Macroscopic analysis of the heart of FS mice. (a,b): macroscopic view of the heart of a MFS
mouse presenting a ear t the level of the right ventricular wall. The tear is indicated i ite arrow in
panel (b). (c,d): macroscopic view of the heart of a MFS mouse presenting vesicles at the level of the right
ventricular wall. Vesicles are indicated with a white arrowhead in panel (d). (e): number of WT and MFS mice
presenting cardiac lesions per age group. Scale bar of panels (a,c) = 1 mm, scale bar of panels (b,d) = 250 µm.
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Figure 3. Microscopic analysis of tissue sections at the level of a myocardial tear and vesicle in the 
right ventricle free wall of the heart of MFS mice. (a,c): standard HE staining of representative 
myocardial tissue sections presenting a myocardial tear (indicated with *) and a vesicle (indicated 
with •). The black arrow in panel (c) indicates the narrow duct in between cardiac muscle lamellae 
connecting the lumen of the vesicle with the lumen of the right ventricle. Black boxes indicate 
localization of panels (b,d,e,g) within the tissue sections. (b,d,e,g): detailed images of HE staining of 
the myocardial lesions and the adjacent tissue. (f,h): picrosirius red staining (collagen deposition) of 
myocardial tissue sections at the level of a tear and vesicle, respectively. (i–l): double fluorescent 
staining of vimentin and collagen (stained red and green, respectively) in myocardial tissue sections 
presenting a myocardial tear and vesicle. Nuclei are stained with DAPI (blue). (m–p): fluorescent 
staining of α-SMA (red) and collagen (green), with nuclei stained blue. Arrowheads indicate α-SMA 
staining of vascular smooth muscle cells in the blood vessel wall. (q,s): immunofluorescence staining 
of myocardial tissue sections at the level of a tear and vesicle, respectively, with an antibody directed 
against the endothelial marker CD31. CD31 positive cells are stained red. Nuclei are stained with 
DAPI (blue). (r,t): immunofluorescence staining of myocardial tissue sections at the level of a tear and 
vesicle, respectively, with an antibody directed against the cardiac myocyte marker ACTN-2. ACTN-
2 positive cells are stained red. Nuclei are stained with DAPI (blue). Boundaries of the tear are 
indicated with white lines in panel (r). Vesicle wall is indicated with white line in panel (t). Insert in 
panel (t) represents positive ACTN-2 staining at the level of the Z-discs of the cardiac myocytes. HE, 
hematoxylin-eosin staining; PSR, picrosirius red staining; RV, right ventricle. 
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ventricle free wall of the hear of MFS mice. (a,c): standard HE st ining of representative myoc rdial
tissue sect ons presenting a myocardial tear (indicated with *) and a vesicle (indicated with •). The black
arrow in panel (c) indicates the arrow duct in between cardiac muscle lamellae connecting the lum n
of the vesicle with th lumen of the right ven ricle. Black boxes indicate localization of panels (b,d,e,g)
within the tissue sections. (b,d,e,g): de ailed images f HE staining of th myocardial lesions a d the
adjacent tissue. (f,h): picrosirius red staining (collagen deposition) of myocardial tissue sections at
the level of a ear and vesicle, respectively. (i–l): double fluorescent staining of vimentin and collagen
( ed red and green, respectively) in myocardial tissue sections presenting a myocardial t ar and
vesicl . Nuclei are stained with DAPI (blue). (m–p): fluorescent staining of α-SMA (red and collagen
(green), with nuclei stained blue. Arrowheads indicate α-SMA staining of vascular smooth muscle
cells in the blood ves el wall. (q,s): immu ofluorescence staining of myocardial tissue sections at the
level of a tear and vesicle, respec ive y, with n ntibody directed against the endothelial marke CD31.
CD31 positive cells are stained red. Nuclei are stain d with DAPI (blue). (r,t): immunofluorescence
staining of myocardial tissue sections at he level of a te and vesicle, respectively, with an antibo y
directed against the cardiac myocyte marker ACTN-2. ACTN-2 positive c lls are stained red. Nuclei
are stained with DAPI (blue). Boundari s of the tear are indicated with white lines in panel (r). Vesicle
wall is in icated with white line in panel (t). Insert in panel (t) represents positive ACTN-2 staining at
the l vel of th Z-discs of the cardiac myocytes. HE, hematoxylin-eosin staining; PSR, picrosirius red
staining; RV, right ventricle.
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2.3.3. Myocardial Wall Structure
Micrographs of cross-sectioned myocardial tissue stained for fibrillin-1 showed an almost complete
loss of fibrillin-1 staining in the sections of MFS mice (Figure 4a,b). Fibrillin-1 staining was abundantly
present in the myocardial tissue sections of WT mice located between the muscle lamellae of the
trabeculated myocardium and at the level of the subepicardial region, with strong fibrillin-1 staining
along the RV free wall. In contrast, very limited fibrillin-1 staining was observed throughout the
myocardial tissue section of the MFS mice. Analysis of HE-stained cardiac sections showed a prominent
decrease in compaction of the ventricular myocardial tissue, demonstrated by more free space between
the cardiac muscle lamellae (representative images in Figure 4c,d). The calculated index for cardiac
non-compaction increased with age in MFS mice and was significantly higher compared to WT
littermates at the age of 3 months (Figure 4e).
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Figure 4. Decreas d compaction f the ventric yocardial tissue in MFS mice correlates with a
decreased presence of fibrillin-1 staining. (a,b): overview picture of fibrillin-1 (red) staining of myocardial
tissue sections of a 3-month-old WT and MFS mouse, respectively. (c,d): representative overview pictures
of HE-stained myocardial tissue sections of a 3-month-old WT and MFS mouse, respectively. (e): graphical
presentation of the myocardial compaction level through the measurement of the average non-compaction
index of the myocardial tissue sections (n/age group = 3). Within each age group, values are normalized
to the WT values. WT and MFS measurements are indicated in grey and black, respectively. Error bars
represents standard error. * p = 0.032 (independent samples test). RV, right ventricle; LV, left ventricle;
WT, wild-type; MFS, Marfan syndrome. Scale bar = 500 µm.
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2.4. TGF-β-Dependent Signaling Pathways
Western-blot analysis was performed on LV myocardial tissue samples of 3-month-old WT and
MFS mice in order to investigate the contribution of canonical (Smad2/3) and noncanonical (ERK1/2)
TGFβ-dependent signaling in the myocardium. The ratio of phosphorylated Smad2, Smad3, and ERK to
total respective proteins was calculated to document the activation of the specific pathway. Compared
to WT littermates, the MFS mice did not show a significant difference in either Smad2, Smad3, or ERK
activation (Mann–Whitney U-test; p ≥ 0.1111, Figure 5).
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Figure 5. Canonical and non-cano ic l TGFβ-depende t signaling in the myocardial tissue of 3-month-old
male WT and MFS mice (n = 4 and 5, respectively). (a): no significant difference could be observed in
Smad2 activation (pSmad2/Total Smad2) between the MFS mice and their WT littermates (Mann–Whitney
U test; p = 0.1111). (b): no significant difference could be observed in Smad3 activation (pSmad3/Total
Smad3) between the MFS mice and their WT littermates (Mann–Whitney U test; p = 0.9048). (c): no
difference in ERK ctivation (pERK/ERK ratio) could be observed between the MFS mice and their WT
littermates (Mann–Whit ey U test; p = 0.4127). Dot plots visualize normalized individual ratios and
mean value per genotype. WT and MFS measurements are indicated in grey and black, respectively.
Error bars represent standard error. WT, wild-type; MFS, Marfan syndrome.
2.5. Electrocardiographic Analysis
2.5.1. Analysis of 24 h Recordings
No significant difference could b observed b tween the average RR-peak intervals of the MFS mice
and their WT littermates (respectively 102.1 ms ± 3.1 and 97.3 s ± 0.9 ms, independent samples test;
p = 0.195). In contrast, decreased heart rate variability (HRV) was observed in the MFS mice, indicated
by a significantly lower full-width at half-maximum interval of the RR-peak interval distribution
histogram co pared to WT mice (respectively 11.3 ms ± 1.0 ms and 16.1 ms ± 1.0 ms, independent
samples test; p = 0.014).
The occurrences of arrhythmic events over 24 h were counted and classified according to the
scheme presented in Appendix B Figure A2 (Table 2). Although arrhythmic events also occurred to a
limited extent in WT mice, the number of arrhythmic events was significantly higher in MFS mice
(Mann–Whitney U-test; p = 0.019). Next, the number of each type of arrhythmic event was calculated
as a relative percentage of the total number of arrhythmic events per genotype. The type of arrhythmic
event highly depended on the genotype (Pearson Chi-square test; p < 0.001) with the main arrhythmic
event in WT mice being sinus arrest (48.7%), whereas in the MFS mice, extrasystoles were the most
abundant (total of 96.3%).
2.5.2. Analysis of Short-Term Heart Rate Variability
A total of 27 paired fragments of two minutes which did not contain arrhythmic events, obtained
from the paired WT and MFS traces studied for long-term analysis, were selected for short-term
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HRV analysis. The standard deviation of normal to normal RR-intervals (SDNN), a frequently used
parameter of HRV, was significantly lower in the MFS recordings compared to the WT recordings,
on average 2.77 ms ± 0.25 ms versus 5.31 ms ± 0.42 ms, respectively (Table 3, Mann–Whitney U-test,
p < 0.001). Furthermore, the frequency-domain (total power, high and low frequency (HF and LF,
respectively)) parameters of HRV, obtained by means of power spectral density (PSD) analysis, were
significantly reduced in the MFS mice compared to the WT mice. Total power decreased 3-fold and HF
decreased 4-fold, while LF had a 10-fold decrease (Table 3, Mann–Whitney U-test; p < 0.001).
Table 2. Absolute total number and relative percentage of arrhythmic events per genotype over 24 h.
Extrasystole
Sinus Arrest Blocked p-Wave AV-Block Total
Single Doublet ≥3
WT A 2 0 0 14 12 3 31
WT B 33 0 0 27 3 0 63
WT C 6 0 0 29 2 0 37
WT D 14 1 0 3 1 0 19
Total Count WT
(Relative %)
55
(36.6%)
1
(0.7%)
0
(0.0%)
73
(48.7%)
18
(12.0%)
3
(2.0%) 150
MFS A 50 4 0 3 7 0 64
MFS B 894 275 2 9 1 0 1181
MFS C 204 27 1 10 7 0 249
MFS D 41 16 0 17 3 1 78
Total Count MFS
(Relative %)
1189
(75.6%)
322
(20.5%)
3
(0.2%)
39
(2.5%)
18
(1.2%)
1
(0.0%) 1572
p = 0.019
Mice are identified per genotype by means of A, B, C and D; WT, wild-type; MFS, Marfan syndrome.
Table 3. Short-term analysis of heart rate variability. n = 27 paired electrocardiogram (ECG) fragments
of two minutes obtained in 4 WT and 4 MFS mice.
WT MFS p-Value
SDNN (ms) 5.31 ± 0.42 2.77 ± 0.25 <0.001
PSD Analysis
Total Power 31.37 ± 5.93 8.98 ± 2.17 <0.001
HF 2.36 ± 0.33 0.55 ± 0.04 <0.001
LF 10.84 ± 1.82 1.06 ± 0.22 <0.001
WT, wild-type; MFS, Marfan syndrome; SDNN, standard deviation of normal R-intervals; PSD, power spectral
density; HF, high frequency; LF, low frequency. Values are mean ± SE.
3. Discussion
Clinical management and surveillance of cardiovascular manifestations of MFS (with a particular
focus on aortic dilatation and mitral valve prolapse) has improved significantly over the past decades,
resulting in a higher life-expectancy of MFS patients [5–7]. This resulted in the appreciation of additional
MFS-related cardiac manifestations, including intrinsic myocardial dysfunction and arrhythmia [8–13],
which had previously remained undetected. MFS mouse models have already been used previously
in order to study the MFS-related cardiac phenotype [11,21,22]. However, the number of studies is
limited, especially in the context of MFS and arrhythmia.
We performed both in vivo and ex vivo in-depth cardiac phenotyping of the hypomorphic
Fbn1mgR/mgR MFS mouse model. We first confirmed the presence of severe aortic dilation extending
from the sinuses of Valsalva to the descending thoracic aorta in MFS mice, which recapitulates
earlier findings in this mouse model [23]. Based on macroscopic evaluation of cardiac structure and
ultrasound measurements of cardiac function, no significant difference was observed between the LV
dimensions and systolic function of MFS mice compared to WT mice. On the other hand, we detected
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diastolic dysfunction, characterized by a significant decrease in E-wave velocity in the MFS mice
compared to their WT littermates. This decrease in E-wave velocity, indicative of slower early filling
of the LV, indicates that fibrillin-1 might play an important role in the active relaxation of the LV
myocardium [2,24]. Similar findings have been observed previously in children with MFS [24,25].
In contrast to our current results, a previous study of the cardiac phenotype of the Fbn1mgR/mgR
mouse model identified a severe dilatation of the LV associated with significant systolic dysfunction [22].
The discrepancy in cardiovascular manifestations between this study and ours might be explained by
environmental factors and/or the genetic background of the mice. It is interesting to note that we used
Fbn1mgR/mgR mice on a congenic C57BL/6J background whereas Cook et al. [22] studied a mixed 129
background ((129X1/SvJ × 129S1/Sv)F1-Kitl+) [22,23]. It has been demonstrated before that the genetic
background of mice can have a significant influence on their cardiovascular physiology both at baseline
and after induction of pathological stress [26–31]. Interestingly, it has previously been shown that the
Fbn1mg∆loxPneo/+ hypomorphic mouse model of MFS also shows phenotypic variability associated with
genetic background, as heterozygous mice showed a more severe aortic and skeletal phenotype on the
129/Sv background than on the C57BL/6 background [32]. Analogous to the approach used to map
genetic modifiers of the aortic and skeletal manifestations in this Fbn1mg∆loxPneo/+ model [33], it will be
interesting to perform a linkage analysis on Fbn1mgR/mgR mice on a mixed C57BL/6J/129 background in
order to identify new modifiers involved in the disease mechanisms leading to the MFS-related cardiac
manifestations. This could reveal mechanisms which might also be relevant to patients with MFS.
In order to begin to investigate the molecular mechanisms responsible for the observed cardiac
manifestations, we assessed the level of activation of the canonical and non-canonical TGFβ-dependent
signaling pathways. Similar to the results from Cook et al. [22], we found no significant changes in
the level of Smad2/3 activation in the myocardial tissue of our Fbn1mgR/mgR mouse model. The level
of ERK1/2 phosphorylation however was also unchanged in the myocardial samples of our MFS
mice, while this pathway was significantly activated in the heart of the MFS mouse model used by
Cook et al. [22] Based on these and other previously published results together with our current data,
the level of activation of ERK1/2 via the non-canonical TGFβ signaling pathway seems to correlate with
the development of LV dilatation and systolic dysfunction in MFS mice [11,21,22]. This pathway is
therefore a likely candidate target of (a) strain-specific genetic modifier(s). Of note, the observation that
our model shows a similar level of aortic dilatation as the model studied by Cook et al. [22], while both
models have a markedly different cardiac phenotype, again, underscores the concept that fibrillin-1
defects lead to primary cardiac manifestations, independent of the aortic phenotype [11,22].
At the level of the RV free wall of the Fbn1mgR/mgR mice, we identified two types of previously
unreported lesions. The outer layer covering the lesions had a similar composition as the epicardium
(fibroblasts embedded in collagen), whereas the inner layer consisted of endothelial cells in contact
with the RV lumen. A subset of fibroblasts stained positive for α-SMA expression, indicating they
had switched to a myofibroblast phenotype. While only a limited number of myofibroblasts were
found in the vicinity of the myocardial tear, a larger number were identified in the subendothelial layer
of the vesicle wall. These findings suggest that the fibroblast lineage switch occurred progressively
during development of the cardiac lesions, likely in response to the altered local mechanical tension.
Myofibroblasts are known to be generated after injury and play a role in tissue remodeling by increasing
collagen deposition and providing contractile force to the weakened tissue. We furthermore observed
a lack of cardiomyocytes in the walls of both types of cardiac lesions. Based on these characteristics,
the lesions can be classified as pseudoaneurysms of the RV free wall [34–36]. We hypothesize that
the etiology of the RV pseudoaneurysms in the Fbn1mgR/mgR mouse model can be assigned to the
reduced ability of the remaining fibrillin-1 fibers to maintain strong structural connections between
adjacent myocardial muscle lamellae. The absence of similar pseudoaneurysm lesions in the LV wall is
surprising considering the higher intraventricular pressures in this cardiac chamber. It is likely that the
increased thickness of the LV myocardial wall, including a relatively fibrillin-1-poor outer compact
myocardium [2], prevents the development of transmural lesions in this cardiac chamber. In humans,
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one case of a LV pseudoaneurysm in a patient with MFS has been reported which was related to apical
venting at the occasion of aortic surgery [37]. The LV pseudoaneurysm was detected by means of
ultrasound imaging and had a cavity width of 40 mm. Our study was performed in mice where, due
to their limited size, we were only able to detect the pseudoaneurysms by means of histology.
To the best of our knowledge, RV pseudoaneurysm formation has not been reported before in
patients with MFS, nor in any MFS mouse model. Nevertheless, a number of explanations can be
put forward for the lack of similar observations in humans. Firstly, the mouse model used for this
study is considered as a Marfan model with an early-onset, severe phenotype; it is conceivable that the
myocardial lesions are part of this specific, severe phenotype. Secondly, detecting small lesions in a
trabeculated right ventricular wall with conventional imaging techniques is particularly challenging and
will require dedicated high-resolution modalities. Thirdly, these lesions may have remained undetected
so far because autopsies are not routinely performed on deceased MFS patients, combined with the
fact that severe (cardiovascular) forms of MFS in humans are rare [34–36]. With this research we hope
to increase awareness for this new myocardial manifestation of MFS, which could potentially lead to
new data regarding the prevalence of this type of cardiac lesions in MFS patients and other MFS mouse
models. Similar to the variable presence of dilated cardiomyopathy in Fbn1mgR/mgR mice, it is likely
that this novel cardiac manifestation is dependent on genetic modifiers associated with the genetic
background, possibly explaining why this phenotype has not been observed previously in another study
using mouse models of MFS. Further research is also warranted to investigate whether these ventricular
pseudoaneurysms in a MFS mouse model are prone to rupture or increase the risk of arrhythmias and
thromboembolism, as is known in the human setting of ventricular pseudoaneurysms [34,35].
Histological analysis of the myocardial tissue showed a highly reduced fibrillin-1 deposition
associated with a decreased compaction of the myocardial tissue (resembling LV non-compaction
cardiomyopathy (LVNC)), which deteriorated with age in MFS mice compared to WT mice. Interestingly,
pathogenic variants in the FBN1 gene [38,39] as well as pathologically increased activation of the TGFβ
signaling pathway, of which the bioavailability is regulated by fibrillin-1 [40–42], have already been
linked with LVNC. Under physiological conditions, fibrillin-1 is abundantly deposited at the level of
the inner trabeculated myocardium [2,3], which is also the area showing the most prominent decrease
in myocardial compaction in our MFS mouse model. Based on these findings, it is plausible that
fibrillin-1 assures a tight connection between adjacent myocardial muscle lamellae, thereby preserving
the compaction of myocardial tissue. A strongly reduced fibrillin-1 deposition in myocardial tissue,
as observed in the MFS mice, might thus weaken this connection which deteriorates with age due to
continuous high pressures and growth of cardiac tissue. Interestingly, the fibrillin fibers in the RV free
wall appear to cross the entire myocardial wall in WT mice, while a significantly decreased compaction
can also be appreciated in this area in the Fbn1mgR/mgR hearts. This is likely linked to the susceptibility
of the RV wall to the development of the pseudoaneurysm lesions which we discovered in this model.
Finally, based on the observed rhythm disorders in MFS patients [14,16], we performed a detailed
assessment of the cardiac rhythm phenotype in the Fbn1mgR/mgR mice. To the best of our knowledge,
this is the first study to perform continuous 24 h ECG recording in a MFS mouse model. Our data
revealed a decreased HRV in MFS mice compared to WT mice which is in accordance with published
data on HRV in patients with MFS [43,44]. A decrease in HRV indicates a possible degree of autonomic
dysfunction, which is associated with an increased risk for malignant ventricular arrhythmia [43–46].
This implies that a decreased HRV could be implemented as a prognostic marker for cardiac rhythm
disorders in MFS patients. Furthermore, the frequency domains of HRV were analyzed by means
of PSD which revealed a reduced absolute power of both the HF and LF bands, and a subsequent
reduction in the total power in the MFS traces compared to the WT traces. This implies that both the
parasympathetic (with HF as the indicator) and sympathetic (with LF as the indicator) activity on the
sinoatrial node is diminished [47]. Unfortunately, the exact mechanism underlying MFS-related HRV
suppression remains unknown. Further research regarding this subject on the MFS mouse model used
in this study might potentially lead to new insights on the molecular mechanisms underlying this
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phenomenon. The analysis of the ECG recordings also revealed a higher prevalence of arrhythmic
events in the MFS mice compared to their WT littermates, with a high frequency of extrasystoles.
Extrasystoles have frequently been reported in patients with MFS [14,16]. Based on the ECG data,
the Fbn1mgR/mgR mouse model clearly recapitulates the ECG abnormalities observed in patients with
MFS, making it an interesting model for further research exploring the pathological mechanisms
leading to the cardiac rhythm disorders associated with MFS. Interestingly, previous studies have
shown that LVNC is associated with an increased occurrence of ventricular arrhythmia [39,48,49].
Since we have demonstrated a strong reduction in myocardial compaction in our MFS mouse model,
we hypothesize that a lack of myocardial connectivity is directly linked to the increased prevalence of
arrhythmic events observed in the Fbn1mgR/mgR mice.
4. Materials and Methods
4.1. Mice
International, national, and institutional guidelines for implementation of good animal welfare
were adhered to. All animal procedures were approved by the local ethical committee of the Faculty of
Medicine and Health Sciences at Ghent University (project identification codes ECD16/14 and ECD18/15,
approved on 18 May 2016 and 23 April 2018, respectively) and were conducted in compliance with
directive 2010/63/EU. Male congenic Fbn1mgR/mgR mice (originally designated as B6.129-Fbn1tm2Rmz/J,
The Jackson laboratory, stock nr.005704) and WT littermates backcrossed for at least 10 generations on
a C57BL/6J background were used for this study. The Fbn1mgR/mgR mice are referred to as “MFS mice”
in this manuscript.
4.2. Ultrasound Analysis
Ultrasound imaging of the aorta and the heart was performed on 3-month-old MFS and WT
mice (n = 12 per group) in order to obtain both functional and structural cardiovascular data. Prior
to ultrasound analysis, mice were anesthetized (1.0–1.5% isoflurane, 0.5 L/min 100% O2) and placed
in supine position on a heated platform connected to ECG electrodes. Subsequently, chest hair was
removed with hair removal cream. Throughout the cardiovascular ultrasound recording, heart rate,
respiration rate, and body temperature were continuously monitored. Recordings were performed with
a Vevo 2100 ultrasound apparatus (Visualsonics, Toronto, ON, Canada) equipped with a high-frequency
linear array transducer (MS 550D, frequency 22–55 MHz). Finally, the obtained ultrasound recordings
were analyzed offline with the Vevo LAB software program (version 3.1.1, Visualsonics), whereby
measurements were performed in triplicate. For the analysis of systolic and diastolic ventricular
parameters, only measurements obtained at a heart rate ≥350 bpm were included. Measurements were
done by a single investigator, blinded to the experimental group. Detailed materials and methods for
the ultrasound analysis are provided in Appendix C.
4.3. Electrocardiographic Analysis
ECG traces of 24 consecutive hours were obtained in MFS mice and WT littermates of 10 weeks of
age (n = 4 per group) according to the protocol described by Steijns et al. [50]. Four days post-operative
data were stored for further offline analysis.
For long-term analysis of the ECG traces, the acquired ECG data were subdivided into fragments
of twenty minutes and subsequently analyzed in Matlab® (version R2018b, MathWorks, Natick, MA,
USA). RR-peak interval (ms) and HRV (ms), represented by the full-width at half-maximum interval
of the RR-peak interval distribution histogram during sinus rhythm, was calculated per fragment.
Furthermore, arrhythmic events were identified semi-automatically based on deviating RR-peak
intervals and subsequent manual evaluation of the ECG traces.
For short-term analysis of the ECG traces, only simultaneously acquired twenty-minute fragments
of a MFS and a WT mouse were selected, based on similar RR-peak intervals. Next, R-peak selection
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and PSD analysis of the HRV were performed on the fragments with the online software platform
PhysioZoo (version 1.2.0, Technion, Haifa, Israel) [51].
4.4. Tissue Isolation
The MFS and WT mice were sacrificed by means of CO2-inhalation using gradual fill (1.0 L/min)
at the age of 1, 2, and 3 months. A thoracotomy was executed in order to isolate the heart, which was
subsequently flushed with a cooled 30 mM KCl solution to induce cardioplegia. After KCl-flushing the
total heart weight was measured and macroscopic pictures were taken using a Leica MZ6 microscope
(Leica Microsystems, Wetzlar, Germany) with a DFC425 color camera (Leica Microsystems) in order to
analyze the heart length and width. For further histological analysis, the hearts were flushed and fixed
for 20 h at 4 ◦C with 4% paraformaldehyde. After paraformaldehyde fixation, the hearts were stored in
a 70% ethanol solution until further processing. Furthermore, the left tibia was amputated, and soft
tissue was removed in order to obtain the tibia length, which was used for normalization of the heart
weights. Heart weight correlates with tibia length and is less prone to fluctuation as observed for body
weight. Furthermore, due to bony overgrowth the body- and tibia-length of the MFS mice was higher
compared to the WT mice. For protein analysis, the left ventricle of the heart was isolated and stored
at –80 ◦C until further processing.
4.5. Histological Analysis
After fixation of the hearts, dehydration and paraffin embedding was performed using an automated
Leica TP1020 tissue processor (Leica Biosystems, Wetzlar, Germany) according to standard histological protocol.
Subsequently, five-µm-thick serial cross-sectional tissue sections at the level of the mid-ventricles were obtained
(Microm HM355S, Thermo Fisher Scientific, Waltham, MA, USA), deparaffinized, and rehydrated before
staining. Hematoxylin-eosin (HE) staining [52] and a picrosirius red (PSR) staining [53] (to stain collagen
deposits) were performed according to standard protocols. Fibrillin-1, fibroblasts, endothelial cells, and cardiac
myocytes were detected by means of immunofluorescence with the primary antibodies anti-fibrillin-1 (pAb
9543, gift from prof. dr. Lynn Y. Sakai [54], 1/100 dilution), anti-vimentin (3932P, Cell Signaling Technology
(CST, Danvers, MA, USA), 1/200 dilution), anti-ACTA2 (staining α-SMA, CST, 1/100 dilution), anti-CD31
(Ab28364, Abcam (Cambridge, UK), 1/100 dilution), and anti-ACTN-2 (Ab9465, Abcam, 1/50 dilution),
respectively. Collagen deposition was also detected by means of fluorescence after overnight incubation
with a collagen hybridizing peptide (15µM, F-CHP, 3Helix Inc., Salt Lake City, UT, USA) subsequent to heat
treatment of the tissue sections. Detailed materials and methods for the (immuno) fluorescence staining
protocol are provided in Appendix C.
Sections were visualized with a Zeiss fluorescence microscope (Axio Observer. Z1, Zeiss, Oberkochen,
Germany) coupled to an Axiocam camera (Zeiss). To obtain an overview image of the entire tissue section
after HE and fibrillin-1 staining, stitching software (Tiles-Zeiss, ZEN pro 2012, Zeiss) was used.
4.6. Myocardial Compaction Calculation
In order to analyze the compaction level of the myocardial tissue at the level of the mid-ventricles
in HE-stained tissue sections, a custom image analysis algorithm was developed using FIJI software
(LOCI, University of Wisconsin, Madison, WI, USA) [55]. Importantly, as staining conditions influence
the results of the analysis, comparisons between the calculated compaction levels were only done on
tissue sections which were stained and imaged at the same time using identical conditions. Tissue
sections were grouped by age, and the result was normalized to WT values. Each age group contained
three WT and three MFS mice and calculations were done in triplicate. Detailed materials and methods
for the calculation of the myocardial compaction are provided in Appendix C.
4.7. TGFβ-Dependent Signalling
Protein levels of the canonical (Smad2/3) and non-canonical (ERK1/2) TGFβ-dependent signalling
pathway were analyzed by means of Western blotting. Tissue samples mixed in lysis buffer (RIPA,
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Sigma-Aldrich, Saint Louis, MO, USA) complemented with protease inhibitors (Complete protease
inhibitor cocktail tablets, Roche, Basel, Switzerland) and phosphatase inhibitors (Cocktail II and III,
Sigma-Aldrich) at a 30% (w/v) ratio were centrifuged at 20,000 g and 4 ◦C for 30 min. Supernatant was
collected and the protein concentration was determined (Pierce BCA protein kit, Thermo Fisher Scientific).
Samples were reduced by addition of dithriothreitol (Sigma-Aldrich) and incubation at 9 ◦C for 5 min.
Next, 30 µg of the sample was run on a NuPage 4–12% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA)
together with a lane marker (Thermo Fisher Scientific), and the proteins were subsequently transferred
onto a nitrocellulose (Invitrogen, for pERK1/2 blots) or PVDF membrane (Invitrogen, for pSmad2/3 blots).
The membrane was blocked in 2% bovine serum albumin (Sigma-Aldrich, for pERK1/2) or 5% ECL
Blocking Buffer (Sigma-Aldrich, for pSmad2/3) and incubated overnight at 4 ◦C with anti-phospho-p44/42
MAPK (pERK, 1/2000, CST), anti-phospho-Smad2 (pSmad2, 1/500, CST) or anti-phospho-Smad3 (pSmad3,
1/1000, CST). Next, the membrane was incubated with the secondary antibody, anti-rabbit IgG HRP-linked
(1/20000, CST) for one hour at room temperature. After incubation with a luminol-based HRP substrate
(Thermo Fisher Scientific), the membrane was scanned using the Chemidoc-it imaging system (UVP,
Sopachem, Nazareth, Belgium). Next, the membrane was treated with stripping buffer (Thermo Fisher
Scientific) and blocked with 2% bovine serum albumin (for total ERK1/2) or 5% ECL Blocking Buffer (for
total Smad2/3) and the process was repeated with the primary antibody against p44/42 MAPK (total
ERK, 1/1000, CST), Smad2 (1/1000, CST), or Smad3 (1/1000, CST). Image J software (version v. 1.44p, NIH,
Bethesda, MD, USA) was used for quantification of the protein bands.
4.8. Statistics
Statistical analysis and generation of graphs were performed with the statistical software package
SPSS (version 25.0, IBM, Armonk, NY, USA), where the acquired measurements were used as dependent
variables and the genotype as independent variables. A Shapiro–WiIk test for normality was applied
to the acquired numerical data. Normal-distributed variables were analyzed with an independent
samples test. Otherwise, variables deviating from a normal distribution and categorical variables were
compared by performing a Mann–Whitney U-test. Statistical analysis of the frequencies of type of
arrhythmic events was performed with a Pearson Chi-Square test. All results are presented as the
mean ± standard error (SE). A p-value < 0.05 was defined as statistically significant (two-sided).
5. Conclusions
This study aimed to contribute to a better understanding of the cardiovascular manifestations of
MFS, using the genetically modified Fbn1mgR/mgR mouse strain as a validated animal model. We found
that the Fbn1mgR/mgR mouse model not only recapitulates the aortic phenotype, but also shows a
distinct cardiomyopathy phenotype characterized by myocardial non-compaction and impaired
diastolic function. Interestingly, we observed lesions in the RV cardiac wall of MFS mice resembling
pseudoaneurysms, which have not yet been reported in previous studies. Finally, we detected heart
rhythm abnormalities in the MFS mouse model similar to those reported in patients with MFS,
which manifested as a decrease in HRV and an increase in extrasystolic events compared to controls.
The presence of RV pseudoaneurysms and heart rhythm abnormalities might be related to the decreased
myocardial compaction that was observed in the Fbn1mgR/mgR mice. Taken together, our results expand
the range of phenotypic manifestations of MFS in the heart, and might potentially contribute to
improved diagnostics and better clinical management for patients with MFS.
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Figure A1. macroscopic analysis of the cardiac dimensions of the dissected hearts of WT and MFS 
mice at the age of 1, 2, and 3 months (n = 12/group). No significant difference in cardiac dimensions 
(length and width) was observed between WT and MFS mice (independent samples test; p ≥ 0.132) 
(a): dot plot visualizes the individual lengths of the dissected hearts and mean value per age group 
and genotype. (b): dot plot visualizes individual width of the dissected hearts and mean value per 
age group and genotype. WT and MFS measurements are indicated in grey and black, respectively. 
Error bars represent standard error. WT, wild-type; MFS, Marfan syndrome. 
  
Figure A1. Macroscopic analysis of the cardiac dimensions of the dissected hearts of WT and MFS
mice at the age of 1, 2, and 3 months (n = 12/group). No significant difference in cardiac dimensions
(length and width) was observed between WT and MFS mice (independent samples test; p ≥ 0.132) (a):
dot plot visualizes the individual lengths of the dissected hearts and mean value per age group and
genotype. (b): d t plot vi ualizes individual width of the dissected hearts and mean value per age
group and genotype. WT and MFS measurements are indicated in grey and black, respectively. Error
bars represent standard error. WT, wild-type; MFS, Marfan syndrome.
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Figure A2: representative traces of arrhythmic events. (a): murine ECG trace in sinus rhythm. (a’): two-
fold magnification of the murine ECG trace of a single heart beat in sinus rhythm marked with the 
different components: the P-wave (P), the QRS-complex (QRS), the J-wave (J), and the T-wave (T). (b): 
murine ECG trace with extrasystole, single. An extrasystole is described as an extra heart beat either 
originating from supraventricular, ventricular or near junctional cardiac tissue. This is represented as 
an extra QRS-complex with an abnormal morphology, mostly followed by a deviant compensatory 
longer RR-interval (indicated with brackets). (c): murine ECG trace with extrasystole, doublet. A 
doublet is represented as two consecutive extrasystoles. (d): murine ECG trace with three consecutive 
extrasystoles. (e): murine ECG trace with sinus arrest. A sinus arrest is represented by a long RR-
interval within the ECG trace in the absence of any ECG activity. (f): murine ECG trace with blocked 
P-wave. A blocked P-wave is represented by the presence of a P-wave (indicated with arrow) without 
subsequent QRS-complex. The resulting long RR-interval is not a multiple of the normal mean RR-
interval. (f’): two-fold magnification of a murine ECG-trace with blocked P-wave. Presence of P-wave 
is indicated with arrow. (g): murine ECG trace with AV-Block. An AV-block is represented by the 
presence of a P-wave (indicated with arrow) without subsequent QRS-complex. The resulting long RR-
interval is a multiple of the normal mean RR-interval. The vertical and horizontal scale bar represent 1 
mV and 100 ms, respectively. 
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Each 2D measurement contained 300 frames obtained at a frame rate of 233–241 frames/sec. For 
color Doppler (CD) and pulse Doppler (PD) images, 100 frames were collected at a frame rate of 40 
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magnification of the murine ECG trace of a single heart beat in sinus rhythm marked with the different
components: the P-wave (P), the QRS-complex (QRS), the J-wave (J), and the T-wave (T). (b): murine ECG
trace with extrasystole, single. An extrasystole is described as an extra heart beat either originating from
supraventricular, ventricular or near junctional cardiac tissue. This is represented as an extra QRS-complex
with an abnormal morphology, mostly followed by a deviant compensatory longer RR-interval (indicated
with brackets). (c): murine ECG trace with extrasystole, doublet. A doublet is represented as two consecutive
extrasystoles. (d): murine ECG trace with three consecutive extrasystoles. (e): murine ECG trace with sinus
arrest. A sinus arrest is represented by a long RR-interval within the ECG trace in the absence of any ECG
activity. (f): murine ECG trace with blocked P-wave. A blocked P-wave is represented by the presence of a
P-wave (indicated with arrow) without subsequent QRS-complex. The resulting long RR-interval is not a
multiple of the normal mean RR-interval. (f’): two-fold magnification of a murine ECG-trace with blocked
P-wave. Presence of P-wave is indicated with arrow. (g): murine ECG trace with AV-Block. An AV-block
is represented by the presence of a P-wave (indicated with arrow) without subsequent QRS-complex.
The resulting long RR-interval is a multiple of the normal mean RR-interval. The vertical and horizontal
scale bar represent 1 mV and 100 ms, respectively.
Appendix C
Appendix C.1. Ultrasound Analysis
Each 2D measurement contained 300 frames obtained at a frame rate of 233–241 frames/sec.
For color Doppler (CD) and pulse Doppler (PD) images, 100 frames were collected at a frame rate of 40
frames/sec. The aortic dimensions and aortic valve function were assessed from a (modified) right
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parasternal aortic arch view. LV dimensions were obtained in M-mode across the parasternal short
axis (PSSAX) view. The percentage of fractional shortening (FS) of the LV, a parameter for LV systolic
function, was calculated as the difference between the LV inner diameter in diastole (LVIDD) and the
inner diameter in systole (LVIDS) divided by the LVIDD. For the assessment of mitral valve and LV
diastolic function, trans-mitral flow patterns including early and late filling velocities were obtained
from the apical four chamber (AP4C) view by means of CD and PD, respectively. Right ventricular
(RV) dimensions were also obtained from the AP4C view in 2D-mode.
Appendix C.2. Histological Analysis
For immunofluorescence staining, heat-induced antigen-retrieval using a pressure cooker (2100
retriever, Laborimpex – Baseclear Lab Products, Leiden, The Netherlands) was done in order to unmask
the epitopes of interest. Depending on the antigen, either a 10 mM sodium citrate buffer (pH 6) or a
13 mM EDTA buffer (pH 8), both supplemented with 1% Tween 20 (Sigma-Aldrich), was used (citrate
for fibrillin-1 and CD31, EDTA for vimentin, α-SMA, and ACTN-2). After antigen-retrieval, the sections
were washed with a tris-buffered saline solution (pH 7.6) supplemented with 0.05% Tween 20 (TBST).
Next, the tissue sections were incubated for one hour at room temperature with 5% bovine serum
albumin (Sigma-Aldrich) in order to reduce non-specific binding of the antibody during further steps.
The stock solution of the collagen hybridizing peptide (100 µM, F-CHP, 3Helix Inc.) was diluted in
5% bovine serum albumin and heated for 5 min at 80 ◦C, after which the solution was cooled down
to room temperature. After overnight incubation at 4 ◦C in a humidified chamber with the primary
antibody and/or collagen hybridizing peptide, the tissue sections were washed multiple times with
TBST. Subsequently, the tissue sections were incubated for one hour at room temperature in a dark
humidified chamber with the appropriate secondary antibody (Anti-rabbit DyLight™ 633 (H + L) or
Anti-Mouse DyLight™ 633 (H + L), Invitrogen, depending on the host of the primary antibody). Finally,
a mounting medium containing DAPI (H-1200, Vectashield, Sigma-Aldrich) was added, after which
tissue sections were covered with a coverslip. The presence of non-specific staining was verified using
controls omitting the primary antibody.
Appendix C.3. Myocardial Compaction Calculation
Stained cardiac tissue areas were selected in the image by setting an appropriate pixel value
threshold, after which the total perimeter of the areas lining gaps or cavities in the myocardial tissue
was calculated. Next, the outer concave perimeter of the cardiac tissue was calculated. When dividing
the total tissue perimeter by the outer concave perimeter, a normalized relative perimeter index is
obtained, which is used as a representative value for myocardial tissue compaction, with higher values
indicating a lower level of compaction.
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